VALNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Valneva SE
Financials through Q4 FY2025, quarter ended Dec 31, 2025Last filing: 20-F on Mar 17, 2026
$5.51−0.10 (-1.78%)
Close on Oct 19, 2026
Valneva statistics
Financials through Dec 31, 2025, price-based ratios appear once a share price is available, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Valneva | Industry median |
|---|---|---|
| Market Cap | €427.14M | €911.72M |
| Enterprise Value | €496.66M | €858.97M |
| PS Ratio | 2.45 | 7.36 |
Enterprise value
| Measure | Valneva | Industry median |
|---|---|---|
| EV / Sales | 2.84 | 3.57 |
Income (trailing twelve months)
| Measure | Valneva | Industry median |
|---|---|---|
| Revenue | €174.66M | €447.40M |
| Gross Profit | €67.52M | €1.08B |
| Operating Income | -€82.06M | -€68.03M |
| Pretax Income | -€114.12M | -€49.18M |
| EBITDA | -€82.06M | -€48.04M |
Margins
| Measure | Valneva | Industry median |
|---|---|---|
| Gross Margin | 38.7% | 42.8% |
| Operating Margin | -47.0% | -33.2% |
| Pretax Margin | -65.3% | -36.6% |
| EBITDA Margin | -47.0% | -28.6% |
| FCF Margin | -32.8% | -24.4% |
Returns
| Measure | Valneva | Industry median |
|---|---|---|
| Return on Capital Employed (ROCE) | -26.9% | -26.9% |
Growth
| Measure | Valneva | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 3.00% | 1.99% |
| Revenue Growth (3Y CAGR) | -21.5% | 13.5% |
| Revenue Growth (5Y CAGR) | 9.62% | 11.0% |
Balance sheet
| Measure | Valneva | Industry median |
|---|---|---|
| Cash & Short-Term Investments | €109.65M | €291.68M |
| Total Debt | €179.17M | €496.91M |
| Net Cash (Debt) | -€69.52M | €87.54M |
| Net Cash Per Share | -0.40 EUR | 1.09 EUR |
| Working Capital | €129.21M | €121.78M |
Financial position
| Measure | Valneva | Industry median |
|---|---|---|
| Current Ratio | 2.38 | 2.81 |
| Quick Ratio | 1.47 | 1.23 |
| Interest Coverage | -1.96 | -0.90 |
Cash flow (trailing twelve months)
| Measure | Valneva | Industry median |
|---|---|---|
| Operating Cash Flow | -€52.89M | -€35.31M |
| Capital Expenditures | -€4.42M | -€4.42M |
| Free Cash Flow | -€57.31M | -€53.81M |
| FCF Per Share | -0.33 EUR | -0.56 EUR |
Efficiency
| Measure | Valneva | Industry median |
|---|---|---|
| Asset Turnover | 0.39 | 0.32 |
| Inventory Turnover | 2.06 | 1.33 |
| Revenue Per Employee | €1.25M | €819.26K |
| Employee Count | 140 | 378 |
Dividends and yields
| Measure | Valneva | Industry median |
|---|---|---|
| FCF Yield | -13.4% | -13.4% |
Shares
| Measure | Valneva | Industry median |
|---|---|---|
| Shares Outstanding | 173,540,000 | 105,361,000 |
| Float | 154,465,000 | 78,574,400 |
| Shares Held by Insiders | 11.0% | 9.05% |
| Shares Held by Institutions | 2.18% | 13.8% |
Taxes
| Measure | Valneva | Industry median |
|---|---|---|
| Income Tax | €1.07M | €1.53M |
Scores
| Measure | Valneva | Industry median |
|---|---|---|
| Altman Z-Score | 1.02 | 1.02 |
Calculated by StockData from Valneva's SEC filings. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.